antagonist therapy" /> antagonist therapy" />

Article

3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    6 3 0 0


Joint Bone Spine
Volume 78, n° 4
pages 352-357 (juillet 2011)
Doi : 10.1016/j.jbspin.2010.12.001
accepted : 6 September 2010
Role for interferon-gamma release assays in latent tuberculosis screening before TNF-⍺ antagonist therapy
 

Huguette Lioté a, , b , Frédéric Lioté c, d, e
a Service de pneumologie et réanimation respiratoire, centre de compétence « Maladies rares pulmonaires », hôpital Tenon, Assistance publique–Hôpitaux de Paris (AP–HP), 4, rue de la Chine, 75970 Paris cedex 20, France 
b Département de santé publique, hôpital Tenon, Assistance publique–Hôpitaux de Paris (AP–HP), 4, rue de la Chine, 75970 Paris cedex 20, France 
c Fédération de rhumatologie (centre Viggo-Petersen), pôle appareil locomoteur, hôpital Lariboisière, AP–HP, 2, rue Ambroise-Paré, 75010 Paris, France 
d UFR de médecine, université Paris-Diderot, 10, avenue de Verdun, 75010 Paris, France 
e Inserm-S606, institut Claude-Bernard, PRES Sorbonne Paris–Cité, 2, rue A.-Paré, 75010 Paris, France 

Corresponding author. Tel.: +33 1 56 01 82 93; fax: +33 1 56 01 70 02.
Abstract

TNF-⍺ antagonist therapy is associated with a risk of severe, extrapulmonary, disseminated tuberculosis, which is fatal in 10% of cases. The risk of tuberculosis is increased four-fold in patients on TNF-⍺ antagonist therapy. The main risk factors are a history of untreated or inadequately treated primary tuberculosis, recent contact with a tuberculosis patient, and residence in or travel to a high-endemicity region. Infection surveillance agencies throughout the world have issued recommendations to ensure the detection and treatment of latent tuberculosis before TNF-⍺ antagonist initiation. These recommendations have returned the incidence of tuberculosis to the level seen before the introduction of TNF-⍺ antagonists. Nevertheless, there is still room for improvement. Recommendations about latent tuberculosis screening include the use of tuberculin skin tests. However, these tests are positive in individuals vaccinated with the BCG vaccine, which leads to overuse of tuberculosis chemoprophylaxis and, therefore, to unnecessary patient exposure to hepatotoxic effects. Furthermore, tuberculin skin tests may be falsely negative in immunosuppressed patients, leading to underuse of tuberculosis prophylaxis. These shortcomings of tuberculin skin tests have generated interest in interferon-gamma release assays (IGRAs). In patients with overt tuberculosis, IGRAs are more sensitive and more specific than tuberculin skin tests. However, the accuracy of IGRAs for diagnosing latent tuberculosis remains unknown, because no reference standard is available. In addition, patients taking immunosuppressant agents to treat systemic disease may exhibit anergia, which complicates the interpretation of IGRAs. Until additional data become available, caution requires that IGRAs be used only when a positive or negative result, as assessed on a case-by-case basis, will help to decide whether tuberculosis chemoprophylaxis is in order.

The full text of this article is available in PDF format.

Keywords : Tuberculosis, TNF-⍺ antagonists, Skin test, Interferon-gamma release assays




© 2010  Société française de rhumatologie@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline